Price · as of 2025
$303.13
Market cap 129.2B
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | $136.35 | -55% |
| P/E | 39.44 | |
| P/B | 5.71 | |
| P/S | 5.10 | |
| EV/EBITDA | 22.22 | |
| PEG | 478.22 | |
| P/TBV | -50.17 |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $44.20 | $66.27 | |||
| 2012 | $55.82 | $78.85 | |||
| 2013 | $70.46 | $74.11 | |||
| 2014 | $79.97 | $69.76 | |||
| 2015 | $93.36 | $60.17 | |||
| 2016 | $117.19 | $95.40 | |||
| 2017 | $151.87 | $89.52 | |||
| 2018 | $172.89 | $131.56 | |||
| 2019 | $173.44 | $122.07 | |||
| 2020 | $227.43 | $138.52 | |||
| 2021 | $236.39 | $166.88 | |||
| 2022 | $255.73 | $149.36 | |||
| 2023 | $349.47 | $211.16 | |||
| 2024 | $373.81 | $225.95 | |||
| 2025 | $334.97 | $244.55 |
Historic valuation ratios
Pick a category, then toggle metrics to compare.
Line items
Line items
Line items
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- CEO
- Kevin A. Lobo
- Employees
- 56K
- Beta
- 0.78
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SYK | Stryker Corporation | $303.13 | 129.2B | $244.55 | -19% | 39.44 | 5.71 | 5.10 | 22.22 | 478.22 | -50.17 | 63.96% | 19.47% | 12.92% | 15.08% | 10.83% | 7.15% | 0.73 | 8.05 | 1.89 | 1.04 | 1.96 | 8.25% | 11.16% | 22.83% | 3.35% | 0.65 | 13.19% | 1.00% | 39.60% | 1.12% | 28.69 | 32.75 | 5.59 | 4.66 |
| AMGN | Amgen Inc. | $410.95 | 221.79B | $377.01 | -8% | 25.36 | 22.59 | 5.32 | 14.26 | 28.74 | -6.05 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.69 | 88.23% | 9.92% | -22.07% | 4.14% | 0.39 | 14.98% | 2.62% | 66.50% | 3.98% | 22.58 | 29.76 | 6.56 | 1.89 |
| BSX | Boston Scientific Corpora… | $49.31 | 73.29B | $60.63 | +23% | 35.39 | 4.22 | 5.10 | 22.09 | 64.11 | -95.73 | 69.01% | 19.78% | 14.38% | 12.57% | 10.11% | 6.96% | 0.51 | 11.38 | 1.62 | 0.91 | 2.03 | 55.20% | 19.87% | 38.30% | 3.57% | 0.83 | 10.90% | 0.00% | 0.00% | 0.35% | 28.38 | 30.81 | 5.61 | 4.23 |
| DHR | Danaher Corporation | $204.76 | 143.94B | $147.35 | -28% | 36.51 | 2.51 | 5.37 | 20.98 | — | -15.64 | 60.93% | 20.91% | 14.71% | 7.08% | 6.70% | 4.49% | 0.35 | 19.38 | 1.87 | 1.25 | 1.99 | -4.73% | 2.90% | -0.68% | 3.99% | 0.94 | 8.03% | 0.67% | 24.30% | 3.96% | 28.37 | 27.71 | 5.93 | 3.93 |
| GILD | Gilead Sciences, Inc. | $133.21 | 165.39B | $125.90 | -5% | 20.94 | 7.85 | 6.05 | 14.25 | 1.24 | -68.79 | 78.83% | 39.74% | 28.90% | 40.49% | 28.04% | 14.42% | 1.10 | 11.43 | 1.55 | 1.23 | 1.28 | 1684.21% | 2.39% | -8.24% | 5.31% | 0.85 | 26.09% | 2.25% | 47.00% | 3.33% | 16.54 | 20.46 | 6.57 | 4.55 |
| HCA | HCA Healthcare, Inc. | $413.36 | 89.49B | $629.87 | +52% | 18.06 | -20.33 | 1.62 | 11.00 | 62.28 | -7.51 | 41.50% | 15.83% | 8.97% | -159.14% | 22.59% | 11.28% | -8.33 | 5.32 | 0.83 | 0.73 | 3.15 | 29.00% | 7.08% | 36.41% | 6.28% | 0.77 | 18.35% | 0.55% | 10.00% | 8.77% | 14.35 | 22.32 | 2.27 | 2.87 |
| MCK | McKesson Corporation | $869.58 | 101.81B | $716.99 | -18% | 20.11 | -44.09 | 0.24 | 13.99 | 40.86 | -5.45 | 3.61% | 1.60% | 1.18% | -224.31% | 507.37% | 6.05% | -3.97 | 26.13 | 0.85 | 0.48 | 0.65 | 49.22% | 12.36% | 9.43% | 5.97% | 0.09 | 546.75% | 0.40% | 8.00% | 5.36% | 15.56 | 17.56 | 0.25 | 6.09 |
| MDT | Medtronic plc | $87.16 | 111.57B | $34.93 | -60% | 22.05 | 2.16 | 2.93 | 12.78 | — | -32.61 | 65.02% | 17.78% | 13.20% | — | — | — | 0.57 | 9.04 | 2.13 | 1.36 | 2.65 | — | — | — | 5.09% | 0.63 | — | 3.41% | 75.20% | 4.38% | 19.39 | 23.11 | 3.45 | 2.77 |
| PFE | Pfizer Inc. | $26.74 | 152.4B | $32.56 | +22% | 18.85 | 1.69 | 2.33 | 13.24 | — | -3.79 | 70.33% | 24.67% | 12.42% | 8.87% | 11.23% | 3.67% | 0.78 | 5.78 | 1.16 | 0.80 | 4.39 | -3.55% | -1.65% | -7.72% | 6.21% | 0.32 | 6.60% | 6.69% | 126.10% | 6.69% | 12.95 | 22.02 | 3.19 | 2.07 |
| SNY | Sanofi | $43.46 | 104.36B | $93.17 | +114% | 15.64 | 1.22 | 1.87 | 7.94 | 33.92 | 22.86 | 72.07% | 20.54% | 16.72% | 7.49% | 9.29% | 4.29% | 0.28 | 15.33 | 1.09 | 0.69 | 1.02 | 46.12% | 5.49% | 72.34% | 11.63% | 0.43 | 11.88% | 6.18% | 96.60% | 12.69% | 10.32 | 9.77 | 2.12 | 1.59 |
| VRTX | Vertex Pharmaceuticals In… | $496.07 | 125.91B | $342.24 | -31% | 30.36 | 6.43 | 9.94 | 24.11 | — | 7.00 | 85.03% | 39.43% | 32.74% | 22.54% | 28.97% | 16.24% | 0.21 | 357.95 | 2.90 | 2.24 | -0.25 | -836.54% | 9.57% | -504.13% | 2.66% | 0.94 | 22.83% | 0.00% | 0.00% | 1.68% | 24.64 | 36.72 | 9.71 | 11.76 |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($136.35 ÷ $303.13) − 1 = -55.02% (IC, example).